Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Quantifying the contribution of transcription factor activity, mutations and microRNAs to CD274 expression in cancer patients.

Scientific reports - 14 Mar 2022

Bruns Imke B, Beltman Joost B

Abstract excerpt

Immune checkpoint inhibitors targeting the programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) axis have been remarkably successful in inducing tumor remissions in several human cancers, yet a substantial number of patients do not respond to treatment. Because this may be partially due to the mechanisms giving rise to high PD-L1 expression within a patient, it is highly relevant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Cell Cycle Proteins
Share to MicroRNAs

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasms

Share to Nuclear Proteins

Share to RNA, Messenger

Share to Transcription Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 35289334
DOI: 10.1038/s41598-022-08356-0
PMCID: PMC8921511

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Quantifying the contribution of transcription factor activity, mutations and microRNAs to CD274 expression in cancer patients.PMID 35289334Read ↗

Integrative In Silico Transcriptomic and Pharmacogenomic Analysis of CD276 as a Candidate Prognostic Biomarker and Therapeutic Target in Bladder CancerSemantic proximity Read ↗

Polymorphisms and overexpression of immune checkpoints PD-1, PD-L1, and CTLA-4 in DLBCL: biomarker insights from a case-control study.Semantic proximity Read ↗

Pan-cancer analysis of patient-specific gene regulatory landscapes identifies recurrent PD-1 pathway dysregulation linked to outcomeSemantic proximity Read ↗

Pan-cancer landscape of CD274 (PD-L1) copy number changes in 244 584 patient samples and the correlation with PD-L1 protein expression.Semantic proximity Read ↗

Gene code CD274/PD-L1 : from molecular basis toward cancer immunotherapySemantic proximity Read ↗

Structural insights into the impacts of non-synonymous single nucleotide polymorphisms in CD274 gene on the PD-1/PD-L1 interaction: An in silico approach.Semantic proximity Read ↗

Pan-cancer analysis of CD274 (PD-L1) mutations in 314,631 patient samples and subset correlation with PD-L1 protein expression.Semantic proximity Read ↗

Upregulation of CD271 Transcriptome in Breast Cancer Promotes Cell Survival via NFκB PathwaySemantic proximity Read ↗

PD-L1 (CD274) promoter methylation predicts survival in patients with acute myeloid leukemiaSemantic proximity Read ↗

PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8+ T-Cell–Driven Antitumor ImmunitySemantic proximity Read ↗

Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlationsSemantic proximity Read ↗

PD‐L1 methylation regulates PD‐L1 expression and is associated with melanoma survivalSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.